Pepstatin , ≥75%(HPLC) , 26305-03-3

Synonym(s):
Pepstatin A;Cathepsin D;Cathepsin D heavy chain;Cathepsin D light chain;CPSD

CAS NO.：26305-03-3

Empirical Formula: C34H63N5O9

Molecular Weight: 685.89

MDL number: MFCD00060740

EINECS: 247-600-0

PRODUCT Properties

• Melting point: 233 °C (dec.)(lit.)
• alpha: D27 -90.3° (c = 0.288 in methanol)
• Boiling point: 695.91°C (rough estimate)
• Density: 1.1340 (rough estimate)
• refractive index: 1.7500 (estimate)
• storage temp.: 2-8°C
• solubility: 10% acetic acid in methanol: 1 mg/mL
• pka: 4.17±0.10(Predicted)
• form: White solid
• color: Colorless needles
• optical activity: Optical rotation: -90.0 ± 5° (c = 0.5, MeOH, 20°C).
• Water Solubility: It is soluble in 10% (v/v) acetic acid in methanol (9:1 methanol:acetic acid) (1 mg/ml), ethanol (1-2 mg/ml with heat up to 60°C), DMSO (5 mg/ml), methanol (1 mg/ml), and acetic acid. Insoluble in benzene, chloroform, water, 1 M NaOH, and ether.
• BRN: 2201362
• Stability: Stable. Incompatible with strong bases, strong acids.
• InChIKey: JKGWASGTXVCDML-LXTPJMTPSA-N
• CAS DataBase Reference: 26305-03-3(CAS DataBase Reference)

Description and Uses

Pepstatin A is a bacterial-derived chemotactic pentapeptide that irreversibly inhibits aspartic proteases, including pepsin, gastricsin, renin, cathepsin E, and cathepsin D. Pepstatin A has been reported to stimulate human neutrophil degranulation (EC₅₀ = 0.75 μM) and super oxide production (EC₅₀ = 1.5 μM). Pepstatin A has been widely used as a research tool in studies of protease mechanisms and biological functions and has been examined as a therapeutic agent for inflammatory conditions including gastric ulcer, edema, and hypertension.

Antiviral;Aspartic proteases irreversible inhibitor

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• Safety Statements: 22-24/25
• WGK Germany: 2
• RTECS: SC6155000
• F: 10
• HS Code: 29241990
• Toxicity: LD50 in mice, rats, rabbits, dogs (mg/kg): 1090, 875, 820, 450 i.p.; all >2000 orally (Umezawa, 1970)